Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Viral vaccines, preclinical safety evaluation

The purpose of this chapter is to review and discuss the preclinical safety evaluation strategy for vaccine approaches to the prophylaxis and treatment of viral diseases. This chapter will discuss the newer approaches to vaccination and will include recombinant proteins, peptides, polysaccharides, DNA plasmids, and viral vectors with and without adjuvants. It is outside the scope of this chapter to discuss whole cells expressing immunogens, live attenuated viruses, bacteria, or parasites. [Pg.684]

Dempster AM, Haworth R. Pre-clinical safety evaluation of viral vaccines. In Cavagnaro JA, ed. Preclinical Safety Evaluation of Biopharmaceuticals. John Wiley Sons Inc. Hoboken, New Jersey. 2008 31 683-712. [Pg.364]

See other pages where Viral vaccines, preclinical safety evaluation is mentioned: [Pg.683]    [Pg.684]    [Pg.686]    [Pg.688]    [Pg.690]    [Pg.692]    [Pg.694]    [Pg.696]    [Pg.698]    [Pg.700]    [Pg.702]    [Pg.704]    [Pg.706]    [Pg.708]    [Pg.710]   


SEARCH



Preclinical

Preclinical safety evaluation

Safety evaluation

Vaccines safety evaluation

Vaccines viral

Viral safety

© 2024 chempedia.info